

Detailed Table of Contents

Chapter 1 Diabetes Statistics	15
Chapter 2 Pathophysiology and Natural History	21
Pathophysiology.....	21
The Natural History of Diabetes.....	25
Chapter 3 Classification	29
Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes of Adults (LADA)	29
Type 2 Diabetes Mellitus	32
Gestational Diabetes Mellitus.....	33
Prediabetes: Impaired Glucose Tolerance (IGT) and Impaired Fasting Glucose (IFG).....	34
Other Specific Types of Diabetes Mellitus	35
Problems With Classification.....	35
Chapter 4 Diagnosis of Diabetes and the 39 Metabolic Syndrome	46
Diabetes and Cardiovascular Disease Risk Assessment	48
The Metabolic or Dysmetabolic Syndrome	53
Chapter 5 Nutrition	53
Nutrition Therapy.....	54
Nutrition Consult	55
Body Weight Considerations.....	57
Caloric Intake.....	58
Nutrient Composition of the Diet	59
Protein Intake	59
Fat Intake	62
Carbohydrate Intake.....	63
Sucrose.....	63
Fructose.....	63
Sodium.....	63
Other Nutritive/Nonnutritive Sweeteners and Fat Substitutes.....	63
Vitamins, Minerals, and Herbs.....	64
Alcohol Intake.....	65
Chapter 6 Exercise	67
Benefits	67
Precautions and Considerations	67
Exercise Prescription	68
Chapter 7 Overview of Pharmacologic Therapy	73
Pathophysiologic Basis of Pharmacologic Therapy.....	74
Importance of Controlling Postprandial Hyperglycemia.....	75
Intensive Therapy in Type 2 Diabetes.....	76
Intensive Glucose Control and Cardiovascular Risk.....	78
CV Risk Reduction	83
CKD Progression Risk Reduction	83
Chapter 8 Oral Agents	87
Chapter 9 Metformin	95
Side Effects of Metformin.....	96

Prescribing Metformin	97
MET/SFU Combination Therapy.....	98
Chapter 10 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors	101
Sitagliptin (Januvia).....	102
Monotherapy Trials.....	102
Use in Patients With Renal Disease	110
Adverse Events With Sitagliptin.....	111
Prescribing Sitagliptin.....	111
Sitagliptin Fixed-Dose Combinations With Metformin (Janumet and Janumet XR).....	112
Prescribing Janumet	112
Prescribing Janumet XR	113
Sitagliptin Fixed-Dose Combination With Ertugliflozin (Steglujan).....	113
Prescribing Steglujan	114
Saxagliptin (Onglyza).....	114
Monotherapy Trials.....	114
Combination Trials.....	115
Adverse Events With Saxagliptin	121
Prescribing Saxagliptin	122
Saxagliptin Fixed-Dose Combination With Metformin XR (Kombiglyze XR).....	122
Prescribing Kombiglyze XR.....	123
Saxagliptin Fixed-Dose Combination With Dapagliflozin (Qtern).....	123
Linagliptin (Tradjenta).....	124
Monotherapy Trials.....	125
Combination or Add-On Treatment	126
Cardiovascular Outcomes Trial of Linagliptin	130
Long-Term Treatment	131
Adverse Events With Linagliptin.....	131
Prescribing Linagliptin.....	132
Linagliptin Fixed-Dose Combination With Metformin (Jentadueto).....	132
Prescribing Jentadueto	132
Linagliptin Fixed-Dose Combination With Empagliflozin (Glyxambi).....	133
Linagliptin Fixed-Dose Combination With Empagliflozin and Metformin (Trijardy XR).....	133
Alogliptin (Nesina)	136
Efficacy	137
Patients with Inadequate Glycemic Control on Diet and Exercise.....	137
Patients with Inadequate Glycemic Control on One or More Agents	141
Adverse Events	146
Prescribing Alogliptin	147
Alogliptin Fixed-Dose Combination with Metformin (Kazano).....	147
Prescribing Kazano	148

Alogliptin Fixed-Dose Combination with Pioglitazone (Oseni).....	148	Prescribing Actoplus Met.....	228
Prescribing Oseni.....	148	Prescribing Duetact.....	229
Summary.....	149	Side Effects with TZDs.....	230
Chapter 11 Sodium-Glucose Transporter 2 (SGLT2) Inhibitors	153	Liver Toxicity.....	230
Canagliflozin (Invokana).....	155	CHF and Edema.....	231
Efficacy.....	156	CVD and Mortality Risk.....	232
Safety.....	157	Summary.....	234
Cardiovascular Outcome Trial of Canagliflozin (CANVAS).....	166	Chapter 13 Alpha-Glucosidase Inhibitors	237
Prescribing Canagliflozin.....	168	Acarbose (Precose).....	237
Dapagliflozin (Farxiga).....	169	Side Effects of Acarbose.....	238
Efficacy.....	169	Prescribing Acarbose.....	238
Cardiovascular Outcome Trial of Dapagliflozin (DECLARE-TIMI 58).....	171	Miglitol (Glyset).....	238
Safety.....	181	Side Effects of Miglitol.....	240
Prescribing Dapagliflozin.....	181	Prescribing Miglitol.....	240
Empagliflozin (Jardiance).....	183	Chapter 14 Sulfonylureas	241
Efficacy.....	184	Side Effects of SFUs.....	242
Safety.....	185	Prescribing SFUs.....	242
Cardiovascular Outcome Trial of Empagliflozin (EMPA-REG OUTCOME).....	191	Second-Generation SFUs.....	243
Prescribing Empagliflozin.....	194	Glimepiride.....	243
Ertugliflozin (Steglatro).....	194	Glipizide.....	244
Efficacy.....	194	Glyburide.....	244
Efficacy in Patients with Moderate Renal Impairment.....	203	Chapter 15 Glinides	245
Safety.....	204	Meglitinide.....	245
Cardiovascular Outcomes with Ertugliflozin.....	204	Repaglinide (Prandin).....	245
Prescribing Ertugliflozin.....	205	D-Phenylalanine Derivative.....	250
SGLT2 Inhibitors and Heart Failure.....	208	Nateglinide.....	250
SGLT2 Inhibitors and Chronic Kidney Disease.....	209	Chapter 16 Bile Acid Sequestrant	255
Selected Warnings and Precautions with SGLT2 Inhibitors.....	213	Colesevelam (Welchol).....	255
Hypotension.....	213	Mechanism of Action.....	255
Ketoacidosis.....	213	Clinical Efficacy.....	255
Acute Kidney Injury and Impairment in Renal Function.....	214	Adverse Events.....	257
Hypoglycemia with Concomitant Use of Insulin and Insulin Secretagogues.....	214	Prescribing Colesevelam.....	257
Genital Mycotic Infections.....	214	Chapter 17 Dopamine Receptor Agonist	261
Lower Limb Amputations.....	214	Bromocriptine Mesylate (Cycloset).....	261
Chapter 12 Thiazolidinediones	219	Mechanism of Action.....	261
Rosiglitazone (Avandia).....	219	Clinical Efficacy.....	261
Pioglitazone (Actos).....	220	Adverse Events.....	262
Monotherapy.....	220	Prescribing Bromocriptine Mesylate.....	263
Combination Therapy.....	220	Chapter 18 Insulin Therapy	265
Pioglitazone Fixed-Dose Combinations (Actoplus Met, Actoplus Met XR, Duetact).....	222	Selecting an Insulin Preparation.....	266
Effect on Lipid Levels.....	223	Application of Intensive Insulin Therapy.....	274
Effect on Cardiovascular Risk Factors.....	223	Combination Therapy.....	276
The PROactive Study.....	226	Premixed Insulin.....	282
Prescribing Pioglitazone.....	228	Multiple-Injection Regimens.....	282
		Insulin Therapy in Obese or Thin Patients.....	286
		Insulin Pump Therapy.....	287
		Tandem t:flex Insulin Pump.....	289
		Insulin Patch Pumps.....	289
		V-Go Device.....	290
		CeQur Simplicity.....	290

Omnipod	290	Combination with Insulin and/or Metformin	397
Smart Insulin Pens	291	Combination with Background Oral Glucose-Lowering	
Newer Insulins	291	Medications: Oral Semaglutide vs Sitagliptin	398
Rapid-Acting Insulins (Lispro, Aspart, Glulisine, Inhaled		Combination with Background Oral Glucose-Lowering	
Human Insulin)	291	Medications: Oral Semaglutide vs SC Dulaglutide	398
Short-Acting Insulin (Regular Human Insulins).....	299	Safety and Tolerability	399
Long-Acting Insulins (Detemir, Glargine U-100)	301	Oral Semaglutide in Patients with Renal Impairment	
Ultralong-Acting Insulin (Glargine U-300, Degludec		(PIONEER-5).....	399
U-100 and U-200).....	307	Cardiovascular Outcome Trial of Oral Semaglutide	
Premixed Formulations	313	(PIONEER-6).....	400
Complications of Insulin Therapy.....	316	Dosage and Administration	401
Weight Gain	316	Switching from Oral to Injectable Semaglutide.....	401
Hypoglycemia	317	Summary	401
Chapter 19 Glucoregulatory Hormones (GLP-1, GIP) and		Mounjaro (Tirzepatide)	401
GLP-1/GIP Receptor Agonists	321	Efficacy	402
Incretins.....	321	Monotherapy	402
GLP-1 Analogues.....	324	Combination with Metformin: Tirzepatide vs Semaglutide....	403
Exenatide (Byetta)	325	Combination with Metformin With or Without SGLT2	
Liraglutide (Victoza).....	337	Inhibitors: Comparison to Insulin Degludec.....	407
Dulaglutide (Trulicity).....	351	Combination with Metformin and/or Sulfonylurea and/or	
Lixisenatide (Adlyxin).....	359	SGLT2 Inhibitors Inhibitors: Comparison to Insulin	
Ozempic (Semaglutide)	367	Glargine.....	408
Efficacy	367	Combination with Bsal Insulin With or Without Metformin..	409
Monotherapy	367	Safety and Tolerability	410
Combination with Metformin and/or Thiazolidinediones	367	Dosage and Administration	410
Combination with Metformin or Metformin with		Fixed-Ratio Combination of a GLP-1 Agonist and	
Sulfonylurea.....	373	Basal Insulin.....	411
Combination with Basal Insulin.....	374	Insulin Degludec/Liraglutide (Xultophy 100/3.6)	411
Combination with Metformin: Semaglutide		Insulin Glargine/Lixisenatide (Soliqua 100/33).....	413
vs Dulaglutide	374	Amylin Analogue	417
Combination with Metformin: Semaglutide vs		Pramlintide (Symlin).....	417
Canagliflozin	375	Clinical Efficacy.....	418
Combination with SGLT2 Inhibitor	375	Weight-Loss Effects of Pramlintide	420
Combination with Metformin, Sulfonylurea, or SGLT		Tolerability.....	421
Inhibitor: Semaglutide vs Liraglutide	376	Hypoglycemia	422
Safety and Tolerability	376	Dosing of Pramlintide	423
Cardiovascular Outcome Trial of Semaglutide		Practical Tips for Patients on Pramlintide.....	423
(SUSTAIN-6).....	377	Chapter 20 Treatment Algorithm	431
Dosage and Administration.....	377	Chapter 21 Assessment of the Treatment Regimen.....	439
Switching from Injectable to Oral Semaglutide.....	379	Measuring Plasma Glucose Concentrations.....	439
Summary	379	Measuring Glycated Hemoglobin.....	441
Rybelsus (Oral Semaglutide)	379	Measuring Other Glycated Proteins.....	442
Efficacy	380	Self-Monitoring of Blood Glucose	444
Monotherapy	380	Reasons for Performing SMBG	445
Combination with Metformin: Oral Semaglutide		Advantages and Disadvantages of SMBG.....	446
vs Empagliflozin	381	SMBG Systems	447
Combination with Sulfonylureas and/or Metformin:		Who Should Perform SMBG?	447
Oral Semaglutide vs Sitagliptin	396	Recommended Frequency of SMBG	448
Combination with SGLT2 Inhibitors and/or Metformin:		SMBG for Patients Who Do Not Take Insulin.....	449
Oral Semaglutide vs SC Liraglutide	396	SMBG for Patients Who Take Insulin	450

Applying SMGB Results to Adjust Insulin Doses.....	4501	Cardiovascular Autonomic Neuropathy (CAN).....	523
Advances in Glucose Monitoring	451	Erectile Dysfunction (ED)	523
Advances in Devices for Bloodletting	452	Diabetic Foot Disorders	526
Advances in Continuous Glucose Monitoring.....	457	Detection and Treatment.....	526
Chapter 22 Acute Complications	461	Chapter 25 Pharmacologic Treatment of Obesity	531
Metabolic	461	Qsymia (Phentermine/Topiramate ER).....	531
Diabetic Ketoacidosis	461	Efficacy	532
Hyperosmolar Hyperglycemic Syndrome.....	472	Safety	532
Hypoglycemia	475	Prescribing Qsymia.....	532
Infection.....	479	Contrave (Naltrexone/Bupropion).....	533
Quality of Life.....	479	Efficacy	534
Chapter 23 Long-Term Complications:		Safety	534
Macrovascular Disease	483	Prescribing Contrave.....	535
Hypertension	484	Saxenda (Liraglutide).....	535
Angiotensin Inhibitors: Angiotensin-Converting		Efficacy	536
Enzyme (ACE) Inhibitors and Angiotensin II Receptor		Safety	537
Blockers (ARBs).....	486	Prescribing Liraglutide.....	538
β -Blockers	488	Wegovy (Semaglutide).....	538
α -Blockers.....	489	Efficacy	539
Calcium Channel Blockers	489	Safety	540
Thiazide Diuretics.....	490	Prescribing Semaglutide	540
Summary	490	Mounjaro (Tirzepatide).....	541
Dyslipidemia.....	490	Conclusion	542
Lipid Profile Abnormalities in Diabetic Patients.....	490	Chapter 26 Prevention of Type 2 Diabetes	545
Cholesterol Measurements.....	492	Diabetes Primary Prevention Trials	545
Lifestyle Modifications.....	495	Da Qing IGT and Diabetes Study	545
Pharmacologic Therapy	497	The Finnish Diabetes Prevention Study (FDPS)	546
Cardioprotective Benefits of Antihyperglycemic Agent		Diabetes Prevention Program (DPP)	547
Pharmacologic Therapy	501	Troglitazone in the Prevention of Diabetes (TRIPOD)	
Renoprotective Benefits of Antihyperglycemic Agent	502	Study	548
Chapter 24 Long-Term Complications:		Study to Prevent Non-Insulin-Dependent Diabetes Mellitus	
Microvascular Disease	507	(STOP-NIDDM)	549
Diabetic Retinopathy	508	Xenical in the Prevention of Diabetes Mellitus in Obese	
Nonproliferative.....	509	Subjects (XENDOS) Trial.....	549
Preproliferative	510	Diabetes Reduction Assessment with Ramipril and	
Proliferative.....	510	Rosiglitazone Medication (DREAM) Trial.....	550
Evaluation and Referral	511	Actos Now for Prevention of Diabetes (ACT-NOW) Trial	550
Treatment	512	Nateglinide and Valsartan in Impaired Glucose Tolerance	
Diabetic Nephropathy	513	Outcomes Research (NAVIGATOR) Trial.....	552
Evaluation	514	Reduced Diabetes Risk in Other Trials	552
Treatment	515	Who Should be Screened	555
Improving Glycemic Control.....	517	Summary	556
Treating Hypertension.....	518	Chapter 27 Resources	561
Limiting Protein Intake	518	Chapter 28 Abbreviations/Acronyms	569
Diabetic Neuropathy	519		
Diabetic Peripheral Neuropathy (DPN).....	520		
Mononeuropathy	521		
Diabetic Amyotrophy.....	521		
Gastroparesis.....	521		
Neurogenic Bladder	522		